Am­gen to buy Hori­zon for $28B; Mer­ck, Mod­er­na tout can­cer vac­cine; FDA ap­proves sec­ond KRAS drug; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We’re tak­ing a hia­tus next week as the lights go out at End­points for the end-of-year hol­i­day, but will re­turn to your in­box on Dec 31, a Sun­day, to re­cap any news over the next two weeks. Thank you so much for your read­er­ship in 2022. End­points Week­ly be­gan al­most two years ago with a blank slate and now has close to 70,000 sub­scribers. Hap­py hol­i­days!

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.